Evolutionary Genomics (Evolutionary Genomics) Total Current Assets : $0.70 Mil (As of Dec. 2022)

View and export this data going back to 2011. Start your Free Trial

What is Evolutionary Genomics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Evolutionary Genomics's total current assets for the quarter that ended in Dec. 2022 was $0.70 Mil.

Evolutionary Genomics Total Current Assets Historical Data

The historical data trend for Evolutionary Genomics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolutionary Genomics Total Current Assets Chart

Evolutionary Genomics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Current Assets

Get a 7-Day Free Trial

0.22

0.12

0.28

0.26

0.70

Evolutionary Genomics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Total Current Assets	Get a 7-Day Free Trial															0.26	1.08	0.92	0.78	0.70

Evolutionary Genomics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Evolutionary Genomics's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.577	+	0.078	+	0	+	0.044
	=	0.70

Evolutionary Genomics's Total Current Assets for the quarter that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.577	+	0.078	+	0	+	0.044
	=	0.70

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Evolutionary Genomics (OTCPK:FNAM) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Evolutionary Genomics's Liquidation Value for the quarter that ended in Dec. 2022 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.577	-	7.946	+	0.75 * 0	+	0.5 * 0
=	-7.37

Evolutionary Genomics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Evolutionary Genomics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolutionary Genomics (Evolutionary Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolutionary Genomics Inc (OTCPK:FNAM) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

4220 Morning Star Drive, Castle Rock, CO, USA, 80108

Website

https://www.evolgen.com

Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.

Executives

Steve B Warnecke	director, 10 percent owner, officer: Chairman, CEO	C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301, LOS ANGELES CA 90077
Virginia P. Orndorff	director	4580 AUGUSTA DR., BROOMFIELD CO 80023
Walter Messier	officer: Secretary / Treasurer	1586 GOSHAWK DRIVE, LONGMONT CO 80504
Mark Virgil Boggess	director	7857 E OAKBROOK CIR, MADISON WI 53717
Sanford Schwartz	director, 10 percent owner	5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Michael Friess	director, 10 percent owner, officer: President/CEO	5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Chloe M Divita	director, officer: Secretary/Treasurer/CFO	5353 MANHATTAN CIRCLE, SUITE 101, BOULDER CO 80303

Evolutionary Genomics (Evolutionary Genomics) Headlines

No Headlines